Gary S Marshall, MD

Academic Title

Professor of Pediatrics

Biography/ Philosophy of Care

Recognition

Publications:

Marshall GS, Blatter M, Aris E, Mesaros N, Miller JM. Antibodies persist for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age. Pediatr Infect Dis J 2013;32:662-668

Marshall GS, Pool V, Greenberg DP, Johnson DR, Sheng X, Decker MD. Safety and immunogenicity of tetanus-diphtheria-acellular pertussis vaccine administered to children 10 or 11 years of age. Clin Vac Immunol 2014;21:1560-1564

Marshall GS, Adams GL, Leonardi M, Petrecz M, Flores SA, Ngai AL, Xu J, Liu G, Stek JE, Foglia G, Lee AW. Immunogenicity, safety, and tolerability of a hexavalent vaccine in infants. Pediatrics 2015;136:e323-e332

Statler VA, Marshall GS. Characteristics of patients referred to a pediatric infectious diseases clinic with unexplained fever. J Pediatr Infect Dis Soc 2016; 5:249-256

Espinosa CM, Fallat ME, Woods CR, Weakley KE, Marshall GS. An approach to the management of pleural empyema with early video-assisted thoracoscopic surgery and early transition to oral antibiotic therapy. Amer Surgeon 2016;82:295-301

Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzeula R, Stek JE, Helmond FA. A double-blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps, rubella, and varicella vaccine (MMRV) manufactured using an alternative process. Hum Vacc Immunother 2016;12:2188-2196

Gebremeskel BG, Zhang D, Goveia MG, Marshall GS, O’Brien MA. Vaccine coverage for United States infants at milestone ages: missed opportunities for vaccination. J Pediatr Infect Dis Soc 2016;5:473-475

Espinosa CM, Marshall GS, Woods CR, Ma Q, Ems D, Nsiah I, Happe LE, Smith MJ. Missed opportunities for human papillomavirus vaccine initiation in an insured adolescent female population. J Pediatr Infect Dis Soc 2017;6:360-365

Lee AW, Jordanov E, Boisnard F, Marshall GS. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers. Expert Rev Vaccines 2017;16:85-92

Statler VA, Marshall GS. Evaluation of prolonged and recurrent unexplained fevers. Pediatr Ann 2018;47:e347-e353

Harel L, Hashkes PJ, Lapidus S, Edwards KM, Padeh S, Gattorno M, Marshall GS. The First International Conference on Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome. J Pediatr 2018;193:265-274

Marshall GS. Vaccine hesitancy, history, and human nature: the 2018 Stanley A. Plotkin Lecture. J Pediatr Infect Dis J 2018;doi: 10.1093/jpids/piy082

Statler VA, Albano FR, Airey J, Sawlwin DC, Jones AG, Matassa V, Heijnen E, Edelman J, Marshall GS. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: a phase 3, randomized, noninferiority study. Vaccine 2019;37:343-351

Marshall GS. The Vaccine Handbook: A Practical Guide for Clinicians (Seventh Edition). Professional Communications, Inc., West Islip, New York, 2018

Clinical Interests/Research

Clinical/Research Interests:

Vaccine development, advocacy and education
Persistent unexplained fever